To study the effects of anti fungal treatment of a subset in CLL patients harboring stereotypic receptors with high specificity for yeasts and molds.

Withdrawn

• Conditions: posaconazole; CLL; 10024324

• Registration Number: NL-OMON36874
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 3

Inclusion Criteria

* Diagnosis of CLL / MBL with mutated IGHV3-7 rearrangements paired to IGKV2-24 encoded light chains;
* Age 18-80 years
* No CLL related treatment during the last 3 months;
* Able to adhere to the study visit schedule and other protocol requirements;
* WHO performance status of * 2;
* Laboratory test results within these ranges: absolute neutrophil count * 1.0 x 109/l, platelet count * 30 x 109/l, creatinine clearance * 60 ml/min, total bilirubin * 25 µmol/L, AST & ALT * 2 x ULN;
* Written informed consent.

Exclusion Criteria

* Known hypersensitivity and/or serious adverse reactions to posaconazole or similar drugs
* Concomitant anti-yeast/mould medication;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>* Decrease in clone size<br /><br>* Decrease in activation status of CLL cells </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>